Ascletis Pharma Inc. (stock code: 01672) released a Next Day Disclosure Return dated 28 October 2025, reporting a repurchase of 100,000 shares. Before the transaction, there were 992,374,320 issued shares excluding treasury shares and 6,584,210 treasury shares, totaling 998,958,530 shares. After the repurchase on 28 October 2025, the number of issued shares excluding treasury shares declined to 992,274,320, while treasury shares rose to 6,684,210, maintaining the overall total of 998,958,530.

Multiple earlier repurchases for cancellation remain pending, covering transactions from April through October 2025 and reflecting a range of repurchase prices from HKD 4.8531 to HKD 11.1022. The document further specifies that on 28 October 2025, 100,000 shares were repurchased on the Hong Kong Stock Exchange at prices between HKD 9.14 and HKD 9.31, for a total of HKD 918,910. These repurchased shares were retained in treasury.

Under a resolution passed on 22 May 2025, the company was authorized to repurchase up to 96,284,628 shares, equating to approximately 0.11% of the issued shares as of that date. The filing also cites a moratorium through 27 November 2025 on new share issuance or treasury share transfers following the most recent repurchase.